Veracyte, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; includes fourth-quarter results. Veracyte is a genomic diagnostics company with tests in thyroid, lung, interstitial lung disease and breast cancer. Most testing revenue came from its Afirma thyroid solution; the company also sells Prosigna products internationally.
Financial performance
| Metric | FY 2020 | FY 2019 | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Total revenue | $117.5 million (-2%) | $120.4 million | $34.5 million (+16%) | $29.7 million |
| Gross margin | 65% (-5 percentage points) | 70% | 68% (+2 percentage points) | 66% |
| Operating expenses, excluding cost of revenue | $111.4 million (+13%) | $98.9 million | $31.4 million (+13%) | Not stated |
| Net loss | $34.9 million | $12.6 million | $8.0 million | $7.5 million |
| Net loss per share, basic and diluted | $0.66 | $0.27 | $0.14 | $0.15 |
| Cash from (used in) operating activities | $(9.7) million | $(3.2) million | $2.3 million | $1.8 million |
FY revenue included $102.0 million testing revenue (-5%), $9.8 million product revenue (up from $0.9 million), and $5.7 million biopharmaceutical revenue (-30%); collaboration revenue was zero versus $4.0 million. Reported genomic classifiers fell 6% to 37,401, while total test volume rose 10% to 44,489, including 7,088 product tests. Q4 testing and product volume was 13,130 tests, up 14% year over year.
At year-end, cash and cash equivalents were $349.4 million, working capital $358.9 million, total assets $457.2 million, and stockholders’ equity $421.2 million. Accounts receivable was $18.5 million. Debt principal was effectively repaid, with a reported $1 outstanding; the balance sheet included $0.8 million of debt obligations, and approximately $1.2 million of final debt-related payments was due in 2022. The company had not drawn its $10 million revolving credit line. FY investing cash use was $3.8 million and financing cash provided was $203.6 million, principally from the August 2020 equity offering.
Changes, outlook and material items
- COVID-19 materially disrupted sample volumes and revenue, particularly in Q2. Second-half reported genomic volume increased 3% year over year as procedures resumed. Management said the pandemic continued to make demand and revenue difficult to forecast.
- FY operating loss widened to $35.4 million from $15.1 million. Higher R&D, G&A and amortization outweighed lower selling and marketing expense. G&A included a $1.5 million revaluation expense for NanoString contingent consideration and a $1.0 million impairment of the MAVIDx investment; cost of testing included a $1.1 million expired-supplies write-down. Stock-based compensation rose to $13.0 million from $9.8 million.
- Management expected continuing losses and elevated investment in product development, commercial expansion and infrastructure. It planned four 2021 launches: a lung-cancer nasal swab test, Percepta Genomic Atlas, Envisia on the nCounter platform and LymphMark lymphoma subtyping. These were plans, not guaranteed outcomes.
- On February 2, 2021, Veracyte agreed to acquire Decipher Biosciences for $600 million cash, subject to customary adjustments and closing conditions; closing was anticipated by April 2021. On February 9, it raised $593.8 million net by issuing 8.55 million shares at $74 per share, materially increasing the share count. Management said cash, offering proceeds, credit availability and expected revenue were sufficient for anticipated needs for at least 12 months.
- Envisia received an initial Medicare ADLT rate of $5,500 effective October 1, 2020. Future pricing was to be based on reported private-payer rates; CMS could recoup some initial payments if those rates were substantially lower. Medicare revenue was 24% of FY revenue and UnitedHealthcare was 11%.
- Principal risks include persistent losses, reliance on Afirma and a limited number of payers, reimbursement-rate and collection uncertainty, COVID-related demand and supply disruptions, regulation of laboratory-developed tests, competition, sole-source suppliers, and execution/integration risks from Decipher and international nCounter expansion. The company reported no material pending legal proceedings. Auditors gave unqualified opinions on the financial statements and internal controls; internal control over financial reporting was deemed effective.
Most important facts for investors to verify
- Whether the Decipher acquisition closed on schedule, its final cash cost and funding, and the resulting integration, revenue and margin performance.
- Whether post-pandemic test volumes and reimbursement recover or grow, especially for Afirma, Percepta and Envisia, and how Medicare/private-payer rate changes affect collections.
- Whether planned 2021 launches and nCounter-based international expansion achieved regulatory clearance, adoption and commercially meaningful revenue.
- The impact of the February 2021 share issuance on dilution and per-share economics, alongside ongoing losses, cash burn and liquidity needs.
- Revenue-estimation sensitivity: FY testing revenue used management estimates of eventual collections, including a $1.5 million favorable adjustment for prior-period tests; the auditor identified diagnostic-service revenue measurement as a critical audit matter.